🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

LIFTOFF! NASA_SLS and Orion Spacecraft launch on their first flight, the #Artemis I mission. Keep checking back for more launch images 📷➡️flic.kr/s/aHBqjzG1pG

Time lapse footage from Orion Spacecraft as #Artemis I journeys to the Moon. Orion is scheduled to make its closest approach to the vicinity of the Moon on Nov. 21.🌙

"This is a whole new chapter in astronomy." Webb researchers found 2 early galaxies, one of which may contain the most distant starlight ever seen. These 2 unexpectedly bright galaxies could fundamentally alter what we know about the very first stars: go.nasa.gov/3XdhoDa

🧐Intriguing data regarding the efficacy of the Wee1 inhibitor, azenosertib, in combination with chemotherapy based on CCNE1 amplification #ASCO23 #gyncsm

My posters at #ASCO2023 : “The effect of megestrol acetate +/- pterostilbene in endometrial cancer” and “Safety and efficacy of PIPAC (pressurized intraperitoneal aerosolized chemotherapy) in ovarian cancer patients with peritoneal metastasis”

Congratulations to Dr. Lugo Santiago Nicole Lugo Santiago (best oral presentation) & Dr. Senguttuvan Rosemary Noel Senguttuvan, MD, FACOG (best poster) for their amazing research efforts and recognition at 2nd annual City of Hope GME Academic Excellence Day! Ernest Han MD #DrMihaeSong Jeff F. Lin City of Hope Surgery

Mayo study: incidence of VTE in patients with advanced-stage EOC treated with NACT and ICS >20% 🚨 Mayo Clinic OB/GYN Amanika SGO IGCS ESGO OncoAlert sciencedirect.com/science/articl…

Check out our newest publication in Annals of Surgical Oncology : “Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer” link.springer.com/epdf/10.1245/s…

🎯Raludotatug deruxtecan R-DXd (CDH6 #AntibodyDrugCongugate) yields objective response rate of 46% and disease control rate of 98% in platinum resistant #OvarianCancer despite a median prior therapies of 4!! #ESMO2023 #gyncsm

Excited to represent City of Hope Surgery in Seoul at the 2023 IGCS Annual Meeting!

Dr. Senguttuvan COH gyn onc fellow presenting data low grade endometrioid uterine cancers w/ TP53 mutations have worse prognosis regardless of new FIGO stage. We need new tx paradigms for these pts #SGOmtg #gyncsm ⁦City of Hope | Orange County⁩ ⁦City of Hope Surgery⁩ ⁦Rosemary Noel Senguttuvan, MD, FACOG⁩

HIPEC for recurrent #ovariancancer (CHIPOR): a RCT, open-label, phase 3 trial - The Lancet Oncology thelancet.com/journals/lanon… OS benefit HR:0.73 ESGO IGCS IJGC Fellows SoMe4GynOnc OncoAlert Gil Morgan, MD